INTERCEPT Blood System for Plasma, pathogen reduction system

Broad spectrum, robust pathogen reduction

The INTERCEPT Blood System for Plasma, pathogen reduction system, provides robust, broad-spectrum pathogen and leukocyte reduction, to reduce the risk of TTI.

what-is-intercept-virus Virus Log Reduction1-5
HIV-1 IIIB, cell-associated ≥6.2
HIV-1 IIIB, cell-free ≥6.1
DHBV (model virus for HBV) 4.4 to 4.5
BVDV (model virus for HCV) ≥4.5
HTLV-I ≥4.1
HTLV-II ≥4.7
West Nile Virus (WNV) ≥6.7
SARS-Associated Coronavirus ≥4.0
Chikunguyna Virus (CHIKV) 6.5
Influenza A virus (H5N1 Avian Influenza) ≥5.7
Parvovirus B19 1.8
Bluetongue Virus ≥4.0
Adenovirus-5 ≥5.6
   
what-is-intercept-bacteria Bacteria Log Reduction1,2,6
Klebsiella pneumoniae ≥6.7
Yersinia enterocolitica ≥6.6
Staphylococcus epidermidis ≥6.6
Treponema pallidum (syphilis) ≥5.4
Borrelia burgdorferi (Lyme disease) ≥9.9
Anaplasma phagocytophilum ≥3.6
   
what-is-intercept-protozoa Protozoan Parasite Log Reduction1,7,8
Plasmodium falciparum (malaria) ≥5.9
Trypanosoma cruzi (Chagas disease) ≥5.0
Babesia microti (babesiosis) ≥4.9
   
leukocyte 80 80 Leukocyte  Log Reduction1
Human T-Cells 4.0
   

REFERENCES

  1. The INTERCEPT Blood System for Plasma Package Insert, December 16, 2014.
  2. Singh Y, et al., (2006), Transfusion. 46: p. 1168-1177.
  3. Tsetsarkin KA, et al., (2013), Am J Trop Med Hyg. 88(6): p. 1163-9.
  4. Sawyer L, et al., (2008), Transfusion. 48(2S): p. 88A.
  5. Stramer SL, et al., (2009), Transfusion. 49(August 2009 Supplement): p. 1S - 29S.
  6. Sawyer L, et al., (2009), Vox Sang. 96(S1): p. 233.
  7. Grellier P, et al., (2008), Transfusion. 48: p. 1676-1684.
  8. Van Voorhis WC, et al., (2003), Antimicrob Agents Chemother. 47(2): p. 475-9.

Achieve high levels of pathogen reduction with INTERCEPT.

*Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.